Psychedelics are suddenly drawing interest from big drugmakers

Taking stock of the drug industry, from the lab to the medicine chest

September 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Psychedelics are suddenly drawing interest from big drugmakers AbbVie's $1.2 billion deal signals pharma's new embrace of psychedelics, with Compass, J&J, and Otsuka all circling the space for future deals By Olivia Goldhill STAT+ | Piercing the hype around Patrick Soon-Shiong's 'Bioshield' cancer treatment In this week's edition of "Adam's Biotech Scorecard," a closer look at the claims made recently by the biotech company ImmunityBio. By Adam Feuerstein STAT+ | Child dies after receiving new experimental gene therapy The treatment by Capsida Biotherapeutics was designed to treat STXBP1 encephalopathy By Jason Mast Erskine Palmer/CDC Dropping hepatitis B shots for newborns would ignore history and endanger children, scientists warn Critics of newborn hepatitis B shots overlook why the CDC adopted the policy, and how cases dropped 99% after universal vaccination began By Eric Boodman STAT+ | Fifty cancer types in one liquid biopsy test: Exact Sciences enters early-detection market Liquid biopsy test Cancerguard can scan for 50 cancers in one blood sample. The company says it marks a new era in early detection, but there are caveats. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser